logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Sehhoon Park

Sungkyunkwan University School of Medicine
H指数:22
被引数:1,904

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study

非小细胞肺癌中除EGFR、ALK和ROS1突变外具有可操作基因改变的患者，采用化疗联合免疫检查点抑制剂的联合治疗：一项回顾性观察性研究

BMC Cancer
IF3.4
2025-10-230
OAAI
Ji Eun Shin; Sehhoon Park; Hyun Ae Jung; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Myung-Ju Ahn
Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial

辅助培美曲塞疗法用于完全切除的Ⅰ期肺腺癌（伴微乳头或实性组织学亚型）的研究：一项单中心、单臂、II期临床试验

eClinicalMedicine
IF10
2025-06-040
OA
Jhingook Kim; Yeong Hak Bang; Sehhoon Park; Hyun-Ae Jung; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Yeong Jeong Jeon; Junghee Lee; Jong Ho Cho; Hong Kwan Kim; Yong Soo Choi; Jae Ill Zo; Young Mog Shim; Jung Hee Kang; Jinseon Lee; Yoon-La Choi; Joungho Han; Soohyun Hwang; Ho Yun Lee; Se-Hoon Lee
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

泛亚适应ESMO临床实践指南，用于癌基因成瘾的转移性非小细胞肺癌患者的诊断，治疗和随访

ESMO OPEN
IF8.3
2024-12-010
PRE
Lee, S. -h.; Menis, J.; Kim, T. M.; Kim, H. R.; Zhou, C.; Kurniawati, S. A.; Prabhash, K.; Hayashi, H.; Lee, D. d. -w.; Imasa, M. S.; Teh, Y. L.; Yang, J. c. -h.; Reungwetwattana, T.; Sriuranpong, V.; Wu, C. -e.; Ang, Y.; Sabando, M.; Thiagarajan, M.; Mizugaki, H.; Noronha, V.; Yulianti, M.; Zhang, L.; Smyth, E.; Yoshino, T.; Park, J. O.; Pentheroudakis, G.; Park, S.; Peters, S.; Ahn, J. B.; Popat, S.
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18

根据EGFR和ALK状态，不可切除的局部晚期III期NSCLC在确定性同步放化疗后维持Durvalumab的临床结局: 韩国癌症研究小组LU-22-18

JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2024-12-010
OA
Choi, Dae-Ho; Kim, Miso; Kim, Young Saing; Park, Keon Uk; Cho, Jang Ho; Kim, Hongsik; Lee, Ki Hyeong; Ahn, Heejoon; Kim, Il-Hwan; Lee, Kyung-Hee; Lee, Gyeong-Won; Yi, Seong Yoon; Ahn, Beung chul; Lee, Min-Young; Jung, Hyun Ae; Park, Sehhoon; Sun, Jong-Mu; Ahn, Jin Seok; Lee, Se-Hoon; Ahn, Myung-Ju
Exploratory biomarker analysis in EGFR mutated NSCLC patients who treated with atezolizumab plus bevacizumab and chemotherapy from phase III ATTLAS trial

ATTLAS III期试验中接受阿替利珠单抗联合贝伐珠单抗和化疗治疗的EGFR突变NSCLC患者的探索性生物标志物分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Kim, H.; Park, S.; Kim, T. M.; Han, J-Y.; Lee, G-W.; Shim, B. Y.; Lee, Y-G.; Kim, S-W.; Ock, C-Y.; Hwang, S.; Lee, Y.; Kim, R.; Jung, H. A.; Sun, J-M.; Lee, S-H.; Ahn, J. S.; Ahn, M-J.
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2024-02-1410
OAAI
Shen, Jeanne; Choi, Yoon-La; Lee, Taebum; Kim, Hyojin; Chae, Young Kwang; Dulken, Ben W.; Bogdan, Stephanie; Huang, Maggie; Fisher, George A.; Park, Sehhoon; Lee, Se-Hoon; Hwang, Jun-Eul; Chung, Jin-Haeng; Kim, Leeseul; Song, Heon; Pereira, Sergio; Shin, Seunghwan; Lim, Yoojoo; Ahn, Chang Ho; Kim, Seulki; Oum, Chiyoon; Kim, Sukjun; Park, Gahee; Song, Sanghoon; Jung, Wonkyung; Kim, Seokhwi; Bang, Yung-Jue; Mok, Tony S. K.; Ali, Siraj M.; Ock, Chan-Young

研究方向

暂未获取到该数据
S
Se‐Hoon Lee
H 指数:87论文数:1,134被引数:3.3万
M
Myung‐Ju Ahn
H 指数:109论文数:1,300被引数:7.2万
H
Hyun Ae Jung
H 指数:30论文数:312被引数:4,631
J
Jin Seok Ahn
H 指数:71论文数:823被引数:2.2万
J
Jong‐Mu Sun
H 指数:56论文数:387被引数:1.2万
Y
Yoon‐La Choi
H 指数:71论文数:509被引数:2.1万
J
Jong‐Mu Sun
H 指数:31论文数:130被引数:5,372
K
Keunchil Park
H 指数:113论文数:958被引数:7.3万
M
Myung‐Ju Ahn
H 指数:24论文数:115被引数:2,213
B
Byoung Yong Shim
H 指数:24论文数:171被引数:2,005